Skip to main navigation
  • Home
  • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
    • Compliance Declaration
  • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
  • Pipeline
    • Menin Inhibition
    • Farnesyl Transferase Inhibitors
    • Posters and Presentations
    • Scientific Manuscripts
    • Access To Investigational Drugs Outside a Clinical Study
  • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
  • Our Medicine
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
      • Calendar Events
      • Corporate Presentations
      • Scientific Publications
    • Corporate Governance
      • Committees and Governance Documents
      • Board of Directors
      • Leadership Team
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
  • Careers
    • Values
    • Life At Kura
    • Benefits
    • Open Positions
  • Contact
    Top Links
    • News & Media
    • Contact
    Main Menu
    • Home
    • About Us
      • Our Commitment
      • The Story Behind Our Name
      • Leadership
      • Board of Directors
      • Grants & Funding
      • Investigator Sponsored Studies
      • Compliance Declaration
    • Our Approach
      • Precision Medicines
      • Overcoming Resistance
      • Novel Biomarkers
    • Pipeline
      • Menin Inhibition
      • Farnesyl Transferase Inhibitors
      • Posters and Presentations
      • Scientific Manuscripts
      • Access To Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
      • Acute Leukemias
      • Head & Neck Cancer
    • Our Medicine
    • Investors
      • Overview
      • Press Releases
      • Events & Presentations
        • Calendar Events
        • Corporate Presentations
        • Scientific Publications
      • Corporate Governance
        • Committees and Governance Documents
        • Board of Directors
        • Leadership Team
      • Financial Information
      • Analyst Coverage
      • FAQs
      • Contact
    • Careers
      • Values
      • Life At Kura
      • Benefits
      • Open Positions
    • Contact
    • MenuMenu

    FAQs

    Submenu
    IR Menu
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Show All

    Where is Kura Oncology incorporated?

    Kura Oncology is incorporated in the state of Delaware.

    Where is Kura Oncology’s corporate headquarters?

    4930 Directors Place, Suite 500
    San Diego, CA 92121
    Ph: 858 500 8800

    Who are the members of Kura Oncology’s Board of Directors?

    You can view our Board of Directors by visiting the Board of Directors section of our website.

    Who are the members of Kura Oncology’s management team?

    You can view our management team by visiting the Management section of our website.

    When is Kura Oncology’s fiscal year-end?

    December 31st

    Who is Kura Oncology’s independent registered public accounting firm?

    Ernst & Young LLP

    On which exchange is Kura Oncology listed and what is the ticker symbol?

    Kura Oncology common stock began trading on NASDAQ on November 5, 2015 under the trading symbol "KURA" . Previously, Kura was quoted on the OTCQB Market under the ticker “KURO”.

    How can I purchase shares?

    Shares can be purchased through a stockbroker of your choice.

    Who is Kura Oncology’s transfer agent and how do I contact them?

    Kura Oncology’s transfer agent is American Stock Transfer and Trust Company, LLC (AST). You can find more information about how to contact AST by clicking here.

    How can I replace my lost stock certificates?

    Please contact our transfer agent, American Stock Transfer, by clicking here. The company can look up your records and make any necessary adjustments. There is a fee involved for replacing lost certificates.

    How do I report a change of mailing address?

    You must send both your old and new addresses to our transfer agent, American Stock Transfer (click here to visit site), by U.S. mail. Each stockholder in question must sign the request for an address change.

    How can I get a copy of Investor materials?

    SEC filings and other investor materials are available under SEC Filings on the Investors section of our corporate website. Additionally, all SEC filings can also be accessed directly from the SEC at www.sec.gov.

    Where can I find recent Kura Oncology press releases?

    You can view our recent press releases by visiting the Press Releases section of our website.

    Where can I find more information on Kura Oncology’s R&D programs?

    You can view information on our platform and programs by visiting the Pipeline section of our website.

    How do I contact Investor Relations with a question or request?

    For investor related questions, please send an email to ir@kuraoncology.com

    If I have questions regarding Kura Oncology that have not been answered, whom should I contact?

    Please visit Contact Us.

    What is Kura's CUSIP number?

    CUSIP: 50127T 109

    Who can I contact if I’m a member of the media?

    For media inquiries, please email Greg Mann at gmann@kuraoncology.com.

    How can I sign up to receive Kura’s press releases and other company information?

    Please visit the Investor Relations section of our corporate website and fill out our "Receive E-mail Alerts" electronic form and select the information you wish to receive. You will be added to Kura’s distribution list.

    Tools

    • Print
    • RSS Feeds
    • Email Alerts
    Footer Links - Top
    • About Us
    • Our Commitment
    • The Story Behind Our Name
    • Leadership
    • Board of Directors
    • Grants & Funding
    • Investigator Sponsored Studies
    • Compliance Declaration
    • Our Approach
    • Precision Medicines
    • Overcoming Resistance
    • Novel Biomarkers
    • Pipeline
    • Menin Inhibition
    • Farnesyl Transferase Inhibitors
    • Posters and Presentations
    • Scientific Manuscripts
    • Access to Investigational Drugs Outside a Clinical Study
    • Patients & Caregivers
    • Acute Leukemias
    • Head & Neck Cancer
    • Our Medicine
    Footer Links - Investors New
    • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Analyst Coverage
    • FAQs
    • Contact
    Footer Links - Careers
    • Careers
    • Values
    • Life at Kura
    • Benefits
    • Open Positions
    Footer Links - News & Media
    • News & Media
    • Press Releases
    • News & Perspecitives
    • Expert Perspectives
    • Media Resources
    01 Footer Links - Contact
    • Contact

    Kura Oncology, Inc. 
    4930 Directors Place, Suite 500 
    San Diego, CA 92121 
    (858) 500-8800

    Kura Oncology, Inc. 
    2 Seaport Lane, Suite 8A 
    Boston, MA 02210 
    (617) 588-3755

    © 2026 Kura Oncology, Inc. All Rights Reserved | Terms of Use| Privacy Policy| Cookie Policy| Consumer Health Data

    Scroll to top